# A Study of Peginterferon Alfa-2a Plus Ribavirin in Early Non-Responder Participants With Chronic Hepatitis C (CHC) Genotype 1, 4, 5, and 6

> **NCT02791256** · PHASE3 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 23 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Ribavirin
- **DRUG:** peginterferon alfa-2a

## Key facts

- **NCT ID:** NCT02791256
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-06
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2016-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02791256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02791256, "A Study of Peginterferon Alfa-2a Plus Ribavirin in Early Non-Responder Participants With Chronic Hepatitis C (CHC) Genotype 1, 4, 5, and 6". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02791256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*